Document:

<PAGE>   1
                                                                     EXHBIT 10.9

                         CONFIDENTIAL TREATMENT REQUEST
                         ------------------------------

     Confidential Portions Of This Agreement Which Have Been Redacted Are Marked
With Brackets ("[***]"). The Omitted Material Has Been Filed Separately With The
Securities And Exchange Commission.

                      HORIZON PHARMACEUTICAL & INPHARMAKON
                             COLLABORATION AGREEMENT

     THIS AGREEMENT made as of the 31st day of October, 1998 ("Effective Date")
between Horizon Pharmaceutical Corporation, a Delaware corporation of 660
Hembree Parkway, Suite 106, Roswell, Georgia 30076 ("Horizon") and InpharmaKon
Corporation, a Delaware corporation of 191 Waukegan Road, Suite 206, Northfield,
Illinois 60099 ("Inpharmakon").

                                    Recitals:
                                    ---------

     A. Horizon is a pharmaceutical product development and marketing company;

     B. Inpharmakon is in the business of developing and assembling literature
based product registration packages for the purpose of enabling marketing
partners to file NDAs (defined below) with the FDA (defined below) for marketing
approval of off label indications for FDA approved pharmaceutical products.

     C. Horizon wishes to collaborate with Inpharmakon and Inpharmakon wishes to
collaborate with Horizon for the purpose of preparing a NDA for submission by
Horizon to the FDA requesting approval to market [***] for the indicated use of
migraine prophylaxis on the following terms and conditions.

     NOW, THEREFORE, the parties agree as follows:

                                    ARTICLE I
                                   Definitions
                                   -----------

     In this Agreement the following expressions shall have the meaning set
forth in this Article.

     1.01  Accounting  Period.  The term  "Accounting  Period"  means a calendar
quarter.

     1.02 Affiliate. The term "Affiliate" means a corporation or business entity
which, directly or indirectly, is controlled by one of the parties or controls
one of the parties. For this purpose, the meaning of the word "control" shall
include, but not be limited to, ownership of fifty percent (50%) or more of the
voting shares or interest of such corporation or business entity.

                                       1

<PAGE>   2

                    [***] - CONFIDENTIAL TREATMENT REQUESTED

     1.03  ANDA. The term "ANDA" means an Abbreviated New Drug Application.

     1.04 Clinical Trials. The term "Clinical Trials" refers to the clinical
trials which Horizon is required to perform under Section 3.01 (ii) below.

     1.05  Confidential Information. The term "Confidential Information" is
defined in Article VII below.

     1.06  FDA. The term "FDA" means the United States Food and Drug
Administration.

     1.07 First Commercial Sale. The term "First Commercial Sale" means the
first sale of the Product to a third party purchaser after NDA approval of the
Product for the Indication.

     1.08 Formulation. The term "Formulation" is defined in Section 3.01(i)
below.

     1.09  Horizon Affiliate. The term "Horizon Affiliate" means an Affiliate of
Horizon.

     1.10 Indication. The term "Indication" means the indication for migraine
prophylaxis.

     1.11  Inpharmakon Affiliate. The term "Inpharmakon Affiliate" means an
Affiliate of Inpharmakon.

     1.12  NDA. The term "NDA" means a New Drug Application submitted to the
FDA requesting approval to market the Product for the Indication.

     1.13  Net Sales. The term "Net Sales" means the gross invoice price of all
Product using the Formulation actually billed by Horizon, Horizon Affiliates or
sublicensees and their Affiliates to unrelated third party customers less (i)
any direct or indirect credits and allowances or adjustments granted to such
customers, including, without limitation, credits and allowances on account of
price adjustments or on account of rejection or return of Product previously
sold, (ii) any trade and cash discounts, and rebates, (iii) any sales, excise,
turnover and similar taxes, and any duties and other governmental charges
imposed upon the production, use or sale of Product or partly processed Product,
and (iv) transportation, insurance and other handling charges provided that such
charges can be reasonably allocated to such billings and are not separately
invoiced.

     1.14  Opportunity Package. The term "Opportunity Package" means the
existing opportunity package already delivered to Horizon, receipt of which is
hereby acknowledged, which describes the Product, the targeted indication, and
an overview of its off label usage and was based upon a review of the published
clinical data for the Product and a patent search to establish prima facie
feasibility.

     1.15  Product. The term "Product" means [***].

                                       2
<PAGE>   3

     1.16  Sublicense. The term "Sublicense" is defined in Section 4.02 below.

                                   ARTICLE II
                                  Collaboration
                                  -------------

     2.01  Scope. Horizon shall work to obtain NDA registration for and
commercialization of the Product indicated for the Indication. Horizon shall
develop a once a day proprietary formulation for the Product and have primary
responsibility for clinical, formulation, manufacturing, and regulatory issues,
and preparation of the NDA for the Product for the Indication.

     2.02. Opportunity Package. Inpharmakon shall give Horizon the exclusive
right to use the Opportunity Package for the purposes of preparing and filing a
NDA for the Product with the FDA for the Indication. Subject to Inpharmakon's
rights upon termination under Article IX below, with effect from the Effective
Date, Inpharmakon shall assert against Horizon no claim to the ownership of the
following intellectual property related to the Product (i) the Formulation
developed by or for Horizon under Section 3.01(i) below, or (ii) the data
arising from the Clinical Trials, nor to the rights to sales, marketing and
distribution for the Product for the Indication. After Horizon has contracted
with a formulator to develop the Formulation, Horizon shall have the right and
power to sublicense its exclusive rights to use the Opportunity Package.

     2.03  Sublicenses. In the event Horizon enters into any Sublicenses,
Horizon shall provide Inpharmakon with a copy of each such Sublicense within 10
days of its execution.

                                   ARTICLE III
                         Responsibilities of the Parties
                         -------------------------------

     3.01. Responsibilities of Horizon. Horizon's responsibilities are as
follows:

          i)   To develop or have developed for it a workable once a day
               formulation (the "Formulation") for the Product or, with
               Inpharmakon's consent which consent will not be unreasonably
               withheld, substitute another formulation (also referred to as the
               "Formulation") with strong marketable differences over available
               generic formulations of the Product;

          ii)  To conduct such clinical trials ("Clinical Trials") as may be
               necessary to prepare and file a NDA for the Product using the
               Formulation and indicated for the Indication; and

          iii) To prepare and file with the FDA a NDA registration package for
               the Product using the Formulation indicated for migraine
               prophylaxis, and exert all reasonable efforts to obtain approval
               of the NDA and commercialize the Product in the United States of
               America.

                                       3
<PAGE>   4

     3.02  License of Formulation. In the event Horizon licenses the Formulation
from a third party, Horizon shall ensure that the license permits Horizon to
assign its interest in the Formulation to Inpharmakon should Inpharmakon
exercise its rights to assume Horizon's rights to the Formulation under Sections
9.01 and 9.02 below.

     3.03  Responsibilities of Inpharmakon: Inpharmakon's responsibilities are
to provide Horizon with the following services:

          i)   To deliver the Opportunity Package to Horizon plus, at no
               additional cost to Horizon, provide additional review of such
               published clinical trials not found in the Opportunity Package as
               the FDA may require after its initial review of the NDA for the
               Indication;

          ii)  To cooperate with and assist Horizon to design, conduct, and
               evaluate the Clinical Trials using the Formulation for the
               purpose of establishing safety and efficacy for the Product
               indicated for the Indication;

          iii) To cooperate with and assist Horizon to assemble the NDA for the
               Product indicated for the Indication, including assembly of
               published clinical literature and summaries;

          iv)  To assist and advise Horizon concerning follow-up information
               required by the FDA in support of the NDA, including attendance
               at meetings with the FDA; and

          v)   Provide other reasonable services as may be agreed by the parties
               in support of Horizon's efforts to obtain approval of the NDA for
               the Product for the Indication.

     3.04  FDA Regulatory Support. In the event that Horizon requires support
with regard to its activities regulated by the FDA over and above Inpharmakon's
services under Section 3.03(ii) through iv) above, Inpharmakon or an Inpharmakon
Affiliate shall provide reasonable support requested by Horizon. Such support
shall be free of charge during the first 8 months of the term of this Agreement.
Thereafter Inpharmakon shall charge Horizon at the provider's (Inpharmakon's or
the Inpharmakon Affiliate's) regular rates presently $120 per hour and Horizon
shall pay such charges within 30 days of the invoice date.

     3.05  Inpharmakon Expenses. Horizon shall reimburse Inpharmakon for
Inpharmakon's documented out of pocket travel expenses related to the
performance of its responsibilities under Section 3.03(ii) through (v) above.
Horizon shall make such reimbursements within 30 days of the invoice date.

                                       4
<PAGE>   5

                    [***] - CONFIDENTIAL TREATMENT REQUESTED

                                   ARTICLE IV
                                  Compensation

     4.01 Fees and Royalties. Horizon shall pay to Inpharmakon as compensation
for its services:

          i)   $[***] within 30 days after the Effective Date;

          ii)  $[***] within 30 days after filing the NDA for the Product for
               the Indication

          iii) $[***] within 30 days after approval of such NDA; and

          iv)  A royalty of [***] of the Net Sales by Horizon or Horizon
               Affiliates payable 45 days after the end of each Accounting
               Period on all sales of the Product using the Formulation for so
               long as Horizon or a Horizon Affiliate sell the Product.

Under no circumstances shall payments received by Inpharmakon under paragraphs
(i) through (iii) of this Section be refundable in whole or in part.

     4.02 Sublicenses. In the event that Horizon grants any third party a
sublicense or other rights (together referred to as a "Sublicense") to make,
have made, use, import, market or sell the Product for the Indication, Horizon
shall pay to Inpharmakon the following royalties:

          i)   If a Sublicense is granted after Horizon enters into a contract
               for development of the Formulation, 50% of the consideration
               (cash and in kind) other than royalties under paragraph (v) of
               this Section received by Horizon less costs incurred by Horizon
               on behalf of the sublicensee and reimbursed by the sublicensee;

          ii)  If a Sublicense is granted after development of the Formulation
               has been completed, 33% of the consideration (cash and in kind)
               other than royalties under paragraph (v) of this Section received
               by Horizon less costs incurred by Horizon on behalf of the
               sublicensee and reimbursed by the sublicensee;

          iii) If a Sublicense is granted after completion of the Clinical
               Trials, 25% of the consideration (cash and in kind) other than
               royalties under paragraph (v) of this Section received by Horizon
               less costs incurred by Horizon on behalf of the sublicensee and
               reimbursed by the sublicensee; or

          iv)  If a Sublicense is granted after approval of the NDA for the
               Product indicated for the Indication, 20% of the consideration
               (cash and in kind) other than royalties under paragraph (v) of
               this Section received by Horizon less costs incurred by Horizon
               on behalf of the sublicensee and reimbursed by the sublicensee;
               and

                                       5
<PAGE>   6
                    [***] - CONFIDENTIAL TREATMENT REQUESTED

          v)   With effect from the First Commercial Sale, 5% of Net Sales by
               sublicencees and their Affiliates.

     4.03  No Release of Section 4.01 Payments. The grant of Sublicenses by
Horizon shall not release Horizon from its obligations to make the payments
required by Section 4.01(i) through (iii) above.

     4.04  Other Indications. Provided that Horizon has paid all of the payments
required by Section 4.01(i) through (iii) above, Horizon shall have the right to
prepare and file ANDAs and NDAs for the Product for indications other than the
Indication. In that event the following provisions shall apply:

          i)   If Product sold by Horizon or Horizon Affiliates for such
               indications use the Formulation, Horizon shall pay to Inpharmakon
               the royalties as provided under Section 4.01(iv) above.

          ii)  If Product sold by Horizon or Horizon Affiliates for such
               indications does not use the Formulation (i.e. it uses another
               formulation useful in the therapeutic range for migraine
               prophylaxis which improves on generically available formulations
               for the Product) but the Product is prescribed for migraine
               prophylaxis, Horizon shall pay to Inpharmakon the royalties as
               provided under Section 4.01(iv) above on all such sales of the
               Product for such prescriptions.

          iii) Horizon shall pay to Inpharmakon the royalties provided under
               Section 4.02(v) on all sales of Product by sublicensees and their
               Affiliates which, if made by Horizon, would be subject to royalty
               payments under paragraphs (i) or ii) of this Section.

          iv)  No royalties shall be due or payable on the Product for such
               indications where the Product uses a formulation that is neither
               useful in the therapeutic range of migraine prophylaxis nor a
               formulation which improves on generically available formulations
               for the Product, and the formulation is not prescribed for
               migraine prophylaxis.

For the purposes of paragraphs (ii) and (iv) of this Section the term "improves"
refers to a technical or non-technical difference in the formulation not found
in generically available formulations for the Product which difference
differentiates the Product from other [***] products (using either the
Formulation or a generically available formulation) for marketing purposes.

                                       6
<PAGE>   7

                                    ARTICLE V
                                 Clinical Trials
                                 ---------------

     For the purposes of Section 3.01(ii) above, Horizon shall contract with LAB
Biosyn of Montreal, Canada or another clinical research organization to perform
clinical trials the same as or equivalent to (1) the program prepared by LAB
Biosyn, a copy of which Inpharmakon shall provide to Horizon contemporaneously
with the execution of this Agreement, or (2) that recommended by the FDA.

                                   ARTICLE VI
                           Payment of Royalties; Audit
                           ---------------------------

     6.01  Payment of Royalties. Horizon shall remit all royalty payments to
Inpharmakon no later than 45 days after the close of each Accounting Period.
Each royalty payment shall be accompanied by a report of the Net Sales subject
to royalty during the Accounting Period. Horizon will deduct withholding taxes
from payments to Inpharmakon only if required by applicable law.

     6.02  Audit Rights. The following provisions shall apply:

          (i)  Inpharmakon, at its own expense, shall have the right, upon
               reasonable prior notice, but no more than once in any year, to
               appoint independent auditors and have them during normal business
               hours, inspect and copy the books and accounts of Horizon,
               Horizon Affiliates and Horizon's sublicensees, if any, related to
               the payment and calculation of royalties arising under this
               Agreement. Horizon shall cooperate and cause Horizon Affiliates
               and sublicensees, if any, to cooperate with such auditors. The
               auditors performing the audit shall disclose to Inpharmakon only
               information relating to the accuracy of records kept and the
               payments made, and shall be under a duty to keep confidential any
               other information obtained from such records.

          (ii) If any such audit establishes that Horizon has underpaid or
               overpaid the amount due, Horizon shall promptly pay any remaining
               amounts due as established by such audit or, in the event of an
               overpayment, Inpharmakon shall promptly refund any such over
               payment. If the underpayment is by 5% or more during any
               Accounting Period, Horizon shall reimburse Inpharmakon for its
               out of pocket expense of such audit, and shall pay to Inpharmakon
               interest on the amount of the underpayment at a rate of 3% above
               the official prime rate, as announced from time to time by
               Citibank NA, New York, or at such lower rate as shall then be the
               maximum rate permitted by law that may be charged on any such
               overdue payment from the date due until paid.

                                       7
<PAGE>   8

                                   ARTICLE VII
                                 Confidentiality

     For a period of 5 years after first disclosure, the parties shall keep
completely confidential, shall not publish or otherwise disclose, and shall not
use for any purpose other than the purposes contemplated by this Agreement, any
Confidential Information without the consent of the disclosing party first had
and obtained. The term "Confidential Information" is that information furnished
by either party to the other in writing and marked "Confidential", or if first
disclosed orally, disclosed in writing and marked "Confidential" within 30 days
after first disclosure. Confidential Information shall not include information
that the receiving party can establish by competent proof:

     (i)  was already known to it prior to disclosure by the disclosing party as
          evidenced by written record or other proof;

     (ii) was or becomes public knowledge through no fault of the receiving
          party;

     (iii)has been received from a third party who did not acquire it directly
          or indirectly from the disclosing party;

     (iv) is independently developed by the receiving party without reference to
          any Confidential Information received from the disclosing party under
          this Agreement; or

     (v)  is compelled to be disclosed in the course of litigation with a third
          party, provided that the compelled party provides the disclosing party
          with notice of such compulsion sufficiently in advance of disclosure
          so as to provide the disclosing party with a reasonable time period to
          seek a protective order.

Notwithstanding the above, the parties may disclose such Confidential
Information to their legal representatives and employees, and to consultants, to
the extent such disclosure is reasonably necessary to achieve the purposes of
this Agreement, obtaining an NDA for the Product for the Indication, and
provided such representatives, employees, and consultants are covered by
obligations of confidentiality with respect to such information no less
stringent than those set forth above.

                                  ARTICLE VIII
                              Term and Termination
                              --------------------

     8.01 Term. The term of this Agreement shall commence on the Effective Date
and shall continue for a period of 10 years thereafter, with automatic renewal
for successive 5 year terms for so long as Inpharmakon, Horizon, and their
respective Affiliates are in substantial compliance with the terms of this
Agreement, unless otherwise terminated earlier pursuant to this Article VIII.

                                       8
<PAGE>   9

                    [***] - CONFIDENTIAL TREATMENT REQUESTED

     8.02 Termination for Material Breach. Either party may terminate this
Agreement in the event the other party materially breaches in the performance of
its obligations under this Agreement, and such breach continues for 90 days
after written notice specifying the breach was provided to the breaching party
by the non-breaching party. Any such termination shall become effective at the
end of such 90 day period unless the breaching party (or any other party on its
behalf) has cured any such breach prior to the expiration of the 90 day period.
A material breach is (i) the assertion of ownership rights by Inpharmakon in
violation of Section 2.02, (ii) the failure by either party to perform in a
timely manner the respective obligations and responsibilities of the parties
under Article III above, (iii) the failure by Horizon to pay the compensation
due under Article IV above, or (iv) the breach by either party of the
confidentiality provisions of Article VII above.

     8.03 Bankruptcy. Either party may terminate this Agreement upon the filing
or institution of bankruptcy, reorganization, liquidation or receivership
proceedings, or upon an assignment of substantially all of the assets for the
benefit of creditors by the other party; provided, however, in the case of an
involuntary bankruptcy proceeding such right to terminate shall only become
effective if the party consents to the involuntary bankruptcy or such proceeding
is not dismissed within 90 days after the filing thereof.

     8.04 Termination by Inpharmakon. Inpharmakon shall have the right to
terminate this Agreement on notice to Horizon in the event of:

     (i)  The failure of Horizon, within [***] after the Effective Date to
          acquire or authorize a formulator to develop a workable once a day
          formulation for the Product.

     (ii) The failure of Horizon, within [***] after the Effective Date to
          complete, in connection with the development of the Formulation, all
          necessary in-vitro clinical studies and complete a clinical
          bioavailability study in a small group of at least 8 patients,
          provided that in the event that technical difficulties with such study
          are encountered, such [***] period will be extended by [***] to
          [***] if the bioavailability study was initiated within such [***]
          period.

     (iii)The failure of Horizon, within [***] after completing the clinical
          bio-availability study on the Formulation under paragraph (ii) above,
          to authorize or initiate the Clinical Trials.

     (iv) The failure of Horizon to file the NDA within [***] after completion
          of the Clinical Trials, including the full statistical analyses.

     (v)  The failure of the FDA within [***] of the filing date of the NDA for
          the Product for the Indication, to approve the NDA unless the FDA is

                                       9
<PAGE>   10

                    [***] - CONFIDENTIAL TREATMENT REQUESTED

          holding up approval pending agreement on labeling requirements for the
          Formulation, in which case the period will be [***];

     (vi) The failure of Horizon to make the First Commercial Sale within [***]
          after receipt of the NDA approval for the Product for the Indication,
          and to thereafter aggressively market and sell the Product for the
          Indication.

     Should Horizon have informed Inpharmakon in due time of serious reasons for
     the delay in the achievement of the events under paragraphs (iii), (iv) or
     (v) above, the parties shall negotiate in good faith an extension or
     extensions of time for Horizon to complete the event delayed without
     Inpharmakon exercising its termination rights provided that such serious
     reasons do not delay the commercialization of the Product beyond [***]
     after the Effective Date. Any waiver by Inpharmakon in one instance shall
     not obligate Inpharmakon to grant any additional or other waivers of
     Horizon's obligations.

                                   ARTICLE IX
                           Consequences of Termination
                           ---------------------------

     9.01 Default of Horizon. If this Agreement is terminated for failure of
Horizon to pay any of the Article IV payments, or is terminated under Section
8.04(i) through (iv) and no default of Inpharmakon was the primary cause of the
default, Inpharmakon shall have the exclusive right to proceed with a NDA for
the Product for the Indication using the Formulation and the data from the
Clinical Trials as has been acquired or developed by Horizon at the date of
termination, and shall have the right to assume Horizon's rights to the same and
the NDA, if applicable, without cost to Inpharmakon or Inpharmakon Affiliates.
In that event Horizon shall release to Inpharmakon its rights to the Opportunity
Package, the Formulation, the related not publicly available information
provided by Inpharmakon or developed by or for Horizon, and registration data
related to the NDA for the Product for the Indication.

     9.02 Failure to Commercialize. If this Agreement is terminated under
Section 8.04(vi) for failure to commercialize the Product for the Indication,
Inpharmakon shall have the exclusive option to purchase Horizon's rights to the
Formulation and the NDA for the Product for the Indication, if applicable, and
the exclusive right to use the data from the Clinical Trials, all for a price
equal to Horizon's booked costs incurred to obtain the same. In that event,
Inpharmakon shall have the right to proceed with a NDA for the Product for the
Indication by itself or through others.

     9.03 No Fault Termination. If this Agreement is terminated under Section
8.04(v) Horizon shall have the right to proceed with an ANDA or NDA with any
formulation of [***] for any indication, including hypertension, without further
obligation to Inpharmakon, including but not limited to no obligation to pay
royalties on Net Sales of any and all formulations of the Product. In that event
Inpharmakon shall have an option to purchase Horizon's rights to the Formulation
and the data from the Clinical Trials at Horizon's booked costs incurred to
obtain the same, but only for the Indication.

                                       10
<PAGE>   11
                    [***] - CONFIDENTIAL TREATMENT REQUESTED

     9.04 Conditions to Inpharmakon Rights. Inpharmakon's rights under Sections
9.01 and 9.02 above are conditioned upon the termination not arising primarily
from problems with the Opportunity Package or Inpharmakon's regulatory support
under Section 3.03ii) or iv). If the termination is as a result of such problems
Inpharmakon shall have no rights to the Formulation or the data from the
Clinical Trials. However, should Inpharmakon so request and have informed
Horizon in due time the reasons for the problems, the parties shall negotiate in
good faith an extension or extensions of time for Inpharmakon to repair or cure
the problems without Horizon exercising its termination rights hereunder. Any
waiver by Horizon in one instance shall not obligate Horizon to grant additional
or other waivers of Inpharmakon's obligations.

     9.05 No Release of Prior Obligations. Termination of this Agreement for any
reason shall not release either party from any liability which, at the time of
such termination, has already accrued to the other party or which is
attributable to a period prior to such termination nor preclude either party
from pursuing all rights and remedies it may have under this Agreement or at law
or in equity with respect to any breach of the Agreement.

     9.06 Survival of Terms. Articles IV, VI, VII, X, XI, XII and XIII, and
Sections 3.02 and 9.01 through 9.05 shall survive the expiration or termination
of this Agreement for any reason.

                                    ARTICLE X
             Representations & Warranties, Disclaimers & Indemnities
             -------------------------------------------------------

     10.01 Representations & Warranties.

           (a) Horizon warrants and represents to Inpharmakon that it has or
prior to commercialization will have the right to manufacture, market and sell
[***], and that such manufacturing, marketing and sale will not infringe the
rights of any third parties.

           (b) Inpharmakon warrants and represents that it has evaluated and, to
the best of its knowledge and belief, accurately reported all clinical
information, including safety and efficacy data, ft has included in the
Opportunity Package.

     10.02 Inpharmakon Disclaimer. Inpharmakon specifically disclaims any
guarantee that the NDA for the Product for the Indication will be successful, in
whole or in part. Inpharmakon will evaluate and accurately report all clinical
information, including safety and efficacy data, it includes in the literature
package for the NDA, but expressly disclaims any responsibility to independently
verify such information for accuracy or completeness. Further, Inpharmakon
expressly disclaims any responsibility for independently verifying that such
clinical information pulled from publicly available or commercial sources does
not infringe third party proprietary rights. However, Inpharmakon has and will
exercise reasonable judgment in deciding whether or not such information should
be used in the NDA. Inpharmakon expressly disclaims responsibility for the
scientific methodologies, clinical protocols and results obtained and reported
in the published literature.

                                       11
<PAGE>   12

     10.03 Indemnification. Horizon shall indemnify, defend and hold Inpharmakon
harmless from and against all product liability claims, actions, suits and other
proceedings, and related costs, including legal fees and expenses, liabilities,
damages and other expenses arising from (i) Horizon's use of the scientific
methodologies, clinical protocols and results referenced in Section 10.02 above
and (ii) the manufacture and sale of the Product. In addition, in the event of
any claims, actions, suits or other proceedings alleging that Horizon's use,
manufacture, marketing or sale of the Product infringes the rights of third
parties, Horizon shall indemnify, defend and hold Inpharmakon harmless from and
against all such claims, actions, suits or other proceedings, and related costs,
including legal fees and expenses, liabilities, damages, and other expenses
incurred by Inpharmakon arising therefrom. Horizon shall not be obligated to
indemnify Inpharmakon as aforesaid unless Inpharmakon promptly notifies Horizon
of the claim, action, suit, or other proceeding and Inpharmakon thereafter
cooperates with and assists Horizon, at Horizon's expense, in the defense of
such claim, action, suit or other proceeding.

                                   ARTICLE XI
                                     Notices
                                     -------

     All information, reports, notices and other communications under this
Agreement will be in writing. Such information, reports, notices and other
communications, and payments will be deemed given to a party when sent to such
party by certified or registered mail, return receipt requested, postage
prepaid; by hand; by facsimile, receipt confirmed; or by overnight courier which
provides confirmation of delivery, at the appropriate address set forth above.
Either party may change its address for the giving of notice by written notice
to the other party as set forth above.

                                   ARTICLE XII
                                   Arbitration
                                   -----------

     Any dispute arising out of the interpretation or performance of this
Agreement or the breach thereof, shall be submitted to arbitration in Chicago,
Illinois in accordance with the Commercial Rules of the American Arbitration
Association. The arbitration award shall be final and binding on the parties.
The arbitrators' fees shall be borne by the losing party. If both parties are
found liable, the arbitrators' fees shall be borne in proportion to the extent
to which each party is found liable. In the event either party is forced to take
legal action in order to enforce an arbitral award hereunder, the defending
party shall pay the claimant party's costs and expenses, including reasonable
attorney fees and expenses, incurred to enforce such arbitral award.

                                  ARTICLE XIII
                                  Miscellaneous
                                  -------------

     13.01 Independent Contractors. The relationship of the parties is that of
independent contractors. The parties are not deemed to be agents, partners or
joint venturers with the other for any purpose as a result of this Agreement or
the transactions contemplated thereby.

                                       12
<PAGE>   13

     13.02 Amendment This Agreement may not be amended, supplemented, or
otherwise modified except by an instrument in writing signed by both parties.

     13.03 Entire Agreement. This Agreement constitutes the entire agreement and
understanding of the parries relating to the subject matter of this Agreement.
It supersedes all previous communications, proposals, representations and
agreements (including the Confidential Disclosure Agreement dated June 25, 1998
and the Term Sheet dated October 13, 1998 between the parties), whether oral or
written, relating to the subject matter of this Agreement.

     13.04 Severance. Should any provision of this Agreement be determined by a
court of competent jurisdiction to violate or contravene any applicable law or
policy, such provision shall be severed or modified to the extent necessary to
comply with the applicable law or policy, and such modified provision and the
remainder of the provisions hereof will continue in full force and effect.

     13.05 Governing Law. This Agreement shall be governed by, and construed in
accordance with, the laws of the State of Illinois, excluding any choice of law
rules which may direct the application of the law of any other jurisdiction.

     13.06 Assignment. Neither party may assign its rights or obligations under
this Agreement without the prior written consent of the other.

     13.07 Section Headings. All section headings are for reference purposes
only and shall not in any way affect the meaning or interpretation of this
Agreement.

     13.08 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be an original, but all of which taken
together shall constitute one and the same agreement.

                                       13
<PAGE>   14

     IN WITNESS WHEREOF, the duly authorized officers of the parties have
executed this Agreement as of the Effective Date.

                                         INPHARMAKON CORPORATION

                                         By:
                                            -----------------------------------

                                         Title:
                                               --------------------------------

                                         HORIZON PHARMACEUTICAL
                                         CORPORATION

                                         By:
                                            -----------------------------------

                                         Title:
                                               --------------------------------

                                       14<PAGE>   1
                                                                   EXHIBIT 10.10

                        CONFIDENTIAL TREATMENT REQUESTED

     Confidential portions of this agreement which have been redacted are marked
with brackets ("[***]"). The omitted material has been filed separately with the
Securities and Exchange Commission.

                       EXCLUSIVE PATENT LICENSE AGREEMENT

     THIS AGREEMENT made and effective this 1st day of January, 2000, by and
between Jame Fine Chemicals, Inc., having a place of business at 100 West Main
Street, Bound Brook, New Jersey 08805 (hereinafter referred to as "Licensor").
and

     Horizon Pharmaceutical, Corporation., having a place of business at 660
Hembree Parkway, Suite 106, Roswell, Georgia 30076 (collectively hereinafter
referred to as "Licensee").

     WHEREAS, Licensor is the owner of the entire right, title and interest in,
to and under Letters Patent of the United States [***] (said patents
collectively referred to as the Licensed Patents); and

     WHEREAS, Licensee is desirous of securing and Licensor is willing to grant
a semi-exclusive license under the Licensed Patents to use, sell and distribute
Finished Dosage Products (defined below) containing to [***];

     NOW, THEREFORE, in consideration of the covenants and obligations
hereinafter set forth to be well and truly performed, the parties hereto hereby
agree as follows:

                                   SECTION ONE

     The following definitions will apply to the respective terms as used
throughout this Agreement.

<PAGE>   2

     (a) "Net Sales" shall mean Licensee's gross invoice price of sales of
Finished Dosage Products covered by the claims of the Licensed Patents in the
Territory to third party customers after deduction of (i) cash, trade and/or
quantity discounts actually allowed; (ii) amounts repaid or credited by reason
of rejection or returns of goods, rebates (including government mandated
rebates) or because of retroactive price reductions unrelated to the sale or
pricing of another product of Licensee; and (iii) freight, postage, and duties
paid for and separately identified on invoices. A sale of a product is deemed to
have occurred upon the earliest of invoicing, shipment or transfer of title in
the product to a party other than Licensee or its affiliates or sublicensees.

     (b) "Baseline Net Sales" shall mean Licensee's actual Net Sales for the
period January 1, 1999 through December 31, 1999.

     (c) "Annual Net Sales" shall mean Licensee's actual Net Sales for a twelve
month period January 1 to December 31 of a given year.

     (d) "Territory" means the United States of America, including its
territories and possessions and Puerto Rico.

     (e) "Contract Year" shall mean the twelve (12) month period commencing on
January 1, 2000 and ending December 31, 2000 for the first Contract Year and
subsequent twelve (12) month periods commencing on the anniversary of the day
immediately following the end of the first Contract Year.

     (f) "Finished Dosage Products" means products that contain active
pharmaceutical ingredients and are in a form ready for sale to a final consumer
(including, without limitation, a liquid suspension or tablet).

                                        2

<PAGE>   3
                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

                                   SECTION TWO

     (a) Licensor agrees to grant and does hereby grant to Licensee under the
Licensed Patents the exclusive right and license to use, sell and distribute
Finished Dosage Products containing [***] covered by the Licensed Patents in the
Territory, except only as to the license rights of Unisource, Inc., a Colorado
corporation (Unisource) and or [***] pertaining to products that contain [***]
and are covered by the Licensed Patents.

     (b) Licensee agrees that it will purchase or otherwise obtain Finished
Dosage Products containing [***] from Unisource, Inc. and its successors or
assigns.

                                  SECTION THREE

     (a) Upon execution of this Agreement, Licensee agrees to pay to Licensor a
license fee of [***] less the [***] advance paid by Licensee to Licensor.

     (b) Effective at the beginning of the first Contract Year, Licensee further
agrees to pay to Licensor, as royalty, [***] of its Annual Net Sales derived by
Licensee from all sales of Finished Dosage Products covered by the Licensed
Patents and made in accordance with the inventions covered thereby; "sales" as
herein employed shall mean sales of the Finished Dosage Products covered by the
Licensed Patents which are made in the United States, its territories,
possessions and Puerto Rico.

     (c) Suspension of royalties:

          (i) Generic. For purposes of this Section THREE (c), "Generic" shall
     mean a generic to [***] or Tanafed but shall not include (A) products that
     infringe upon the Licensed Patents or (B) products made from raw material
     supplied by Licensor prior to the effective date of this Agreement.

                                        3
<PAGE>   4

                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

          (ii) Suspension. If a Generic enters the market, then, per a
     determination made as of December 31 of such year of entry and December 31
     of each subsequent year of this Agreement (all of which calendar years,
     including the year of entry, shall collectively be referred to as the
     "Calendar Years Potentially Suspended"), Licensee's obligation for the
     royalty may be suspended for one or more Calendar Years Potentially
     Suspended as determined as follows. Licensee is not obligated for the
     royalty for any given Calendar Year Potentially Suspended if i) the gross
     sales in ounces in the entirety of such Calendar Year Potentially Suspended
     do not exceed the Threshold Sales (hereinafter defined) applicable to that
     Calendar Year Potentially Suspended AND ii) the Generic is available in the
     Territory at any time during such Calendar Year Potentially Suspended.

          (iii) Refund of Royalties. Accordingly, if Licensee is not obligated
     for the royalty in a given Calendar Year Potentially Suspended, then,
     within 30 days after the end of that calendar year, Licensor shall (A)
     refund royalties to Licensee so that the net effect of such refund will be
     that Licensee did not pay any royalties for such calendar year and (B) pay
     Licensee interest on the royalties refunded at the prime rate as of
     December 31 of the calendar year for which royalties are being refunded. In
     the event Licensee is not obligated for the royalties in a given calendar
     year, Licensee may still be obligated for the royalty in future year(s).

          (iv) THRESHOLDS. The Threshold Sales are as follows:

<TABLE>
<CAPTION>
<S>                               <C>

Potential                         Threshold Sales applicable to the
                                  corresponding Calendar Year

Suspension                        Potentially Suspended

Calendar Year

  2000                            Gross sales of [***] ounces (which is [***] of
                                  Licensee's gross sales in ounces in 1999 which
                                  was [***] ounces)

  2001                            [***] of the gross sales (in ounces) in
                                  calendar years 1999 or 2000, whichever is
                                  higher

  2002                            [***] of the gross sales (in ounces) in
                                  calendar years 1999, 2000 or 2001, whichever
                                  is highest

  2003 and thereafter             [***] of the gross sales (in ounces) in
                                  ounces) in calendar years 1999, 2001, 2002
                                  or any other subsequent Calendar Year
                                  Potentially Suspended, whichever is highest
</TABLE>

                                        4
<PAGE>   5

                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

          (v) Partial Refund of Licensing Fee: If in the year 2000, there is a
     Generic available AND Licensee's Gross Sales do not exceed [***] ounces,
     then Licensor will refund one half of the up-front fees paid upon execution
     of this agreement.

          (v) Example:

2000
Based on a calculation made as of December 31, 2000, i) if Licensee's gross
sales (in ounces) for calendar 2000 (including gross sales in calendar 2000
prior to the entry of the generic) do not exceed [***] ounces, AND ii) the
Generic is available in the Territory at any time during such Calendar Year
Potentially Suspended then Licensee would not be obligated for royalties for the
entirety of calendar 2000 and would be refunded calendar 2000 royalties
accordingly; and

2001
Based on a calculation made as of December 31, 2001, i) if Licensee's gross
sales in ounces for calendar 2001 do not exceed [***] of the gross sales (in

                                        5

<PAGE>   6

                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

ounces) in calendar years 1999 or 2000, whichever is highest, AND ii) the
Generic is available in the Territory at any time during such Calendar Year
Potentially Suspended then Licensee would not be obligated for royalties for the
entirety of calendar 2001 and would be refunded calendar 2001 royalties
accordingly; and

2002
Based on a calculation made as of December 31, 2002, i) if Licensee's gross
sales (in ounces) for calendar 2002 do not exceed [***] of the gross sales (in
ounces) of calendar years 1999, 2000 or 2001, whichever is highest, AND ii) the
Generic is available in the Territory at any time during such Calendar Year
Potentially Suspended then Licensee would not be obligated for royalties for the
entirety of calendar 2002 and would be refunded calendar 2002 royalties
accordingly; and

2003 and thereafter
Based on a calculation made as of December 31 of 2003 and of each year
thereafter, if i) Licensee's gross sales (in ounces) for any such calendar year
do not exceed [***] of the gross sales (in ounces) of the previous calendar year
of this Agreement in which Gross sales (in ounces) were the highest, AND ii) the
Generic is available in the Territory at any time during such Calendar Year
Potentially Suspended, then Licensee would not be obligated for royalties for
the entirety of the calendar year ending on the December 31 on which such
calculation was made, and would be refunded royalties for such calendar year
accordingly.

     (d) The term of this Agreement shall be from the date hereof to the later
of the expiration of either of the Licensed Patents or any reissue, continuation
or extension of the Licensed Patents. In the event that Licensor becomes the
owner of or has rights to patents in addition to the Licensed Patents which
additional patents pertain to the products covered by the Licensed Patents, the
term of this Agreement shall automatically extend to the expiration of such
additional patents. In any event, Licensee may continue to renew this Agreement
for [***] year renewal periods beyond the above-referenced patent expiration

                                        6

<PAGE>   7

dates by providing Licensor written notice of its intent to so renew prior to
such patent expiration dates.

                                  SECTION FOUR

     It is mutually understood and agreed that the sale of compositions covered
by the Licensed Patents may be subject to approval and/or regulation by the Food
and Drug Administration or other applicable government agency and in the event
that such approval is refused or such regulation prohibits the sale of products
covered by the Licensed Patents, Licensee shall have the right to cancel this
Agreement and the license herein granted to it; in the event of such
cancellation, Licensee shall not be liable to Licensor for the payment of any
royalties hereunder or any additional license fees, as the case may be.

                                  SECTION FIVE

     All royalties provided for by this License Agreement shall be due and
payable quarterly and Licensee agrees to pay to Licensor on or before the last
day of each of the months of February, May, August and November of each Contract
Year during which this Agreement is in force, the total amount of royalties due
and payable on account of its operations under this Agreement during the
calendar quarter immediately preceding said dates.

                                   SECTION SIX

            Licensee agrees that it will render to Licensor with each such
royalty payment a written statement setting forth the total Annual Net Sales
from its royalty-bearing sales during the period covered by such statement and
Licensee agrees to keep a separate record in a suitable book or set of books
provided for the purpose, in sufficient detail to enable the royalties payable
hereunder to be determined, and further agrees that it will permit such book or
set of books to be examined by an auditor or accountant, authorized by Licensor,
at any reasonable time during business hours to the extent necessary to verify

                                       7

<PAGE>   8

                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

the records and payments here provided for, it being agreed that such auditor or
accountant shall make his report to Licensor in such manner that names of
customers or other information deemed confidential by Licensee will not be
disclosed to Licensor.

                                  SECTION SEVEN

     In the event that Licensor makes or acquires any improvements or additional
patents in or relating to the inventions covered by the Licensed Patents, such
improvements and patents shall be and are hereby included as part of the
Licensed Patents upon the same terms and conditions as the said Licensed
Patents; Licensee shall not be obligated to pay to Licensor any further or
additional royalty or other consideration for the license to any such additional
improvements or patents. Licensee's only obligation to Licensor shall be to
continue to pay the royalty stipulated in Section Three until the expiration of
the last such patent or any reissue or extension thereof unless otherwise
provided herein.

                                  SECTION EIGHT

     Licensee shall, at its option, with the prior written consent of Licensor,
have power to institute and prosecute, at its own expense, suits for
infringement of the Licensed Patents, and, Licensor will cooperate in such suits
by furnishing such evidence, documents, and testimony as may reasonably be
required, and if required by law, Licensor will join as a party plaintiff in
such suits. All expenses in such suits will be borne entirely by Licensee and
Licensee will pay to Licensor [***] of any excess of recoveries over expenses
(including without limitation attorney fees) in such suits.

                                        8

<PAGE>   9

                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

                                  SECTION NINE

     (a) Licensor warrants, that effective as of the date hereof, Licensor and
Unisource have established a business relationship (the Relationship) whereby
Unisource Inc. may purchase [***] and [***] from Jame Fine Chemicals and the
Relationship shall continue for a duration at least as long as the duration of
this Agreement. Licensor further warrants that pursuant to the Relationship, for
a period of 12 months, and thereafter it will not increase the prices for such
Active Pharmaceutical Ingredients by an amount exceeding the percentage increase
in the PPI (except that Licensor may increase such price to reflect documented
increases in direct costs which include labor, raw materials, utilities and
direct overhead costs to maintain its existing profit margin which increases
will not be subject to the PPI cap, but which increases shall have been
documented to the satisfaction of Licensee and Unisource). Licensor will
decrease the prices of the Active Pharmaceutical Ingredients to reflect
decreases in the cost of such manufacturing components. Under the terms of the
Relationship, Licensor will notify Unisource and Licensee of the change in
dollars per Kg and the effective date of any price change of each Active
Pharmaceutical Ingredient utilized by Unisource for Finished Dosage Product
supplied to Licensee.

     (b) Licensor warrants that, if for any reason Licensor is unable to supply
product to meet all of the needs of Unisource, Unisource shall have the
exclusive right, along with [***], to receive Licensor's production of the
products covered by the Licensed Patents based on the respective amounts of such
products ordered during the preceding twelve (12) month period.

                                   SECTION TEN

     (a) Licensor represents and warrants that, as of the date hereof, it has
entered into a license agreement with [***], a corporation having a place of

                                        9

<PAGE>   10

                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

business in [***], in a form similar to this Agreement and whereby [***] has a
semi-exclusive license to the Licensed Patents as they pertain to [***]. (b)
Licensor warrants that in its Relationship and Licensing Agreement with
Unisource, (i) Unisource is prohibited from selling or distributing Finished
Dosage Products containing [***] to any person or entity other than Licensee and
(ii) Unisource does not have the right to sell [***] as a stand alone active
ingredient.

     (b) Licensor warrants that (a) it owns the Licensed Patents; (b) it has the
right to license the Licensed Patents to Licensee; (c) no third party has filed
any civil action against Licensor in connection with the Licensed Patents or
notified Licensor that the Licensed Patents violate such third party's patent,
trademark, copyright, or trade secret rights; (d) to the best of Licensor's
knowledge, the Licensed Patents do not infringe any third party's copyright or
patent; (e) it has not granted to any third party any rights in or to the
Licensed Patents that are inconsistent with any right granted to Licensee under
this License Agreement or that will adversely affect any exercise by the
Licensee of its rights granted under this License Agreement.

     (c) Licensor agrees to indemnify, defend, and hold harmless Licensee
against any losses, liabilities, claims, damages, costs, and expenses (including
reasonable attorney's fees) (the "Claims") that result from Licensor's material
breach of any of the above warranties. Licensor shall assume all expenses with
respect to the defense, settlement, adjustment, or compromise of any Claims as
to which this section requires Licensor to indemnify, defend, or hold harmless
Liensee and, upon such assumption, shall have sole control over the defense,
settlement, adjustment, or compromise of such Claims; provided, however, that
(i) Licensor shall obtain prior written approval of Licensee, which Licensee
shall not unreasonably withhold, before entering into any settlement,
adjustment, or compromise of such Claims; and (ii) Licensee may, if it so
desires, employ counsel at its own expense to assist in the handling of such

                                       10
<PAGE>   11

claim or undertake sole control of the defense, settlement, adjustment, or
compromise of such Claims.

                                 SECTION ELEVEN

     In the event that Licensee defaults or breaches any of the provisions of
this License Agreement or fails to account for or pay to Licensor any of the
royalties due and payable to Licensor hereunder, Licensor reserves the right to
cancel the license here granted upon sixty (60) days' written notice to
Licensee; provided, however, that if Licensee, within the sixty (60) day period
referred to, cures the said default or breach, the license herein granted shall
continue in full force and effect until the expiration of the Licensed Patents
or any reissue, continuation or extension thereof. In the event of the
termination of the license herein granted by Licensor to Licensee, Licensee
shall not be relieved of the duty and obligation to pay in full royalties
accrued and due and payable at the effective date of such termination.

                                 SECTION TWELVE

     In the event of any adjudication of bankruptcy, appointment of a Receiver
by a court of competent jurisdiction, assignment for the benefit of creditors or
levy of execution directly involving Licensee, this Agreement shall thereupon
forthwith terminate and no longer be of any further force and effect.

                                SECTION THIRTEEN

     This Agreement shall be governed by, interpreted in accordance with, and
enforced under the laws of the State of New Jersey, U.S.A. (regardless of its or
any other jurisdiction's choice of law principles), or, as necessary, the laws
of the United States of America.

                                       11
<PAGE>   12

                                SECTION FOURTEEN

     This Agreement constitutes the entire agreement between the parties hereto
respecting the subject matter hereof, and supersedes and terminates all prior
agreements respecting the subject matter hereof, whether written or oral, and
may be amended only by an instrument in writing executed by both parties hereto.

                                 SECTION FIFTEEN

     (a) Indemnification by Licensee - Licensee shall indemnify and hold
Licensor harmless against all liability, damage, cost or expense (including
reasonable attorneys' fees) arising out of the promotion, distribution, sale or
use of products made using the products supplied by Licensor or its designee to
Licensee hereunder, including those resulting from any personal injury
(including death) to any person including employees, servants, or agents of
Licensee, except to the extent such liability, damage, cost or expense is caused
by the negligence, omission, failure to act, intentional malfeasance, willful
misconduct, and/or breach of the warranties or other obligations of Licensor
under this agreement. In the event of any claim arising under this indemnity,
prompt notice of such claim shall be given by Licensor to Licensee which shall
have the right to conduct the defense in respect thereto, but Licensor may have
counsel present at its own expense and shall be entitled to participate in the
defense of any such claim. Licensor shall cooperate with Licensee in such
defense at the expense of Licensee. No settlement of any such matter shall be
made without the written approval of Licensee and Licensor, which will not be
unreasonably withheld.

     (b) Indemnification by Licensor - Licensor shall indemnify and hold
Licensee harmless against all liability, damage, cost or expense (including

                                       12
<PAGE>   13

reasonable attorneys' fees) arising out of any breach of this Agreement by
Licensor and/or the manufacturing, packaging and storing of products supplied by
Licensor.

                                 SECTION SIXTEEN

     This Agreement and the license herein granted shall be binding upon and
inure to the benefit of each of the parties hereto, their successors and the
assigns of the entire business relating thereto of each of the parties.

                                SECTION SEVENTEEN

     If any term or provision of this Agreement is found held to be excessive,
or invalid, void or unenforceable, the offending term or revision shall be
deleted or revised to the extent necessary to be enforceable, and, if possible,
replaced by a term or provision which, so far as practicable, achieves the
legitimate aims of the parties.

                                SECTION EIGHTEEN

     Any notice or other communication given by either party hereto to the other
party relating to this Agreement shall be sent by registered or certified mail,
return receipt requested, addressed to such other party at the address set forth
above. Changes of address shall be given in the same manner as any other notice.

     IN WITNESS WHEREOF, the parties hereto have caused this instrument to be
executed by their duly authorized representatives as of the day and year first
above written.

                                JAME FINE CHEMICALS, IN.

Attest:                         By: ______________________________
                                Title: ___________________________

                                HORIZON PHARMACEUTICALS, INC.

Attest:                         By: ______________________________
                                Title: ___________________________

                                       13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}]]